Neptune Technologies & Bioressources Inc. is Granted Method of Use Patent for Cardiovascular Disease Applications in Europe; EFSA Stamps Final Approval for NKO(R) NOVEL FOOD and PARNUTS Status

LAVAL, Quebec, Oct. 29, 2009 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX-V:NTB) is pleased to announce that the patent entitled "KRILL EXTRACTS FOR PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR DISEASES" was issued in Europe successfully without opposition. "This new Method of Use patent is a critical achievement eliminating competition from the European cardiovascular market with any krill extract, such as krill oils other than Neptune Krill Oi,l" said Dr. Tina Sampalis, Chief Scientific Officer of Neptune.